Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.

For advanced treatment of diseases such as cancer, multicomponent, multifunctional nanoparticles hold great promise. In the current study we report the synthesis of a complex nanoparticle (NP) system with dual drug loading as well as diagnostic properties. To that aim we present a methodology where chemically modified poly(lactic-co-glycolic) acid (PLGA) polymer is formulated into a polymer-lipid NP that contains a cytotoxic drug doxorubicin (DOX) in the polymeric core and an anti-angiogenic drug sorafenib (SRF) in the lipidic corona. The NP core also contains gold nanocrystals (AuNCs) for imaging purposes and cyclodextrin molecules to maximize the DOX encapsulation in the NP core. In addition, a near-infrared (NIR) Cy7 dye was incorporated in the coating. To fabricate the NP we used a microfluidics-based technique that offers unique NP synthesis conditions, which allowed for encapsulation and fine-tuning of optimal ratios of all the NP components. NP phantoms could be visualized with computed tomography (CT) and near-infrared (NIR) fluorescence imaging. We observed timed release of the encapsulated drugs, with fast release of the corona drug SRF and delayed release of a core drug DOX. In tumor bearing mice intravenously administered NPs were found to accumulate at the tumor site by fluorescence imaging.

[1]  Chenjie Xu,et al.  Size and Concentration Effect of Gold Nanoparticles on X-ray Attenuation As Measured on Computed Tomography. , 2008, Chemistry of materials : a publication of the American Chemical Society.

[2]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[3]  X. Sui,et al.  Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery , 2012, International journal of nanomedicine.

[4]  J. Dorsman,et al.  Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. , 2007, Biochemical pharmacology.

[5]  David J. Waxman,et al.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.

[6]  Ming-hui Li,et al.  HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia–reperfusion injury in rats , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  T. Park,et al.  Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release , 1999, Pharmaceutical Research.

[8]  A. Secord,et al.  Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer , 2012, International Journal of Gynecologic Cancer.

[9]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[10]  A. Karydas,et al.  PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[11]  B. Sunderland,et al.  An ion pairing approach to increase the loading of hydrophilic and lipophilic drugs into PEGylated PLGA nanoparticles. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  Axel Thran,et al.  Atherosclerotic Plaque Composition : Analysis with Multicolor CT and Targeted Gold Nanoparticles 1 , 2010 .

[13]  Robert Langer,et al.  Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. , 2012, Nano letters.

[14]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[15]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[16]  Chad A Mirkin,et al.  Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. , 2011, Nano letters.

[17]  Claudia Calcagno,et al.  Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. , 2011, ACS nano.

[18]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[19]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[20]  Steven P Schwendeman,et al.  Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. , 2008, International journal of pharmaceutics.

[21]  Nam-Trung Nguyen,et al.  Micromixers?a review , 2005 .

[22]  Roger A. Rajewski,et al.  Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.

[23]  Z. Fayad,et al.  Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. , 2012, Chemical communications.

[24]  K. Edwards,et al.  Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. , 2003, Biophysical journal.

[25]  B. Rigas,et al.  Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. , 2012, Nanomedicine.

[26]  J F Hainfeld,et al.  Gold nanoparticles: a new X-ray contrast agent. , 2006, The British journal of radiology.

[27]  Robert Langer,et al.  Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.

[28]  R. Murray,et al.  Does core size matter in the kinetics of ligand exchanges of monolayer-protected Au clusters? , 2005, Journal of the American Chemical Society.

[29]  Mathias Brust,et al.  Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system , 1994 .

[30]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[31]  Mohammad Hedayati,et al.  Preliminary study of injury from heating systemically delivered, nontargeted dextran-superparamagnetic iron oxide nanoparticles in mice. , 2012, Nanomedicine.

[32]  K. Jensen,et al.  Synthesis of micro and nanostructures in microfluidic systems. , 2010, Chemical Society reviews.

[33]  D. Gewirtz,et al.  Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. , 1994, Molecular pharmacology.

[34]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[35]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[36]  J. Loo,et al.  Cellular uptake of Poly‐(D,L‐lactide‐co‐glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method , 2011, Biotechnology journal.

[37]  C. Mirkin,et al.  Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation , 2012, Proceedings of the National Academy of Sciences.

[38]  V. Fuster,et al.  Effect of Computed Tomography Scanning Parameters on Gold Nanoparticle and Iodine Contrast , 2012, Investigative radiology.

[39]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.